Astegolimab clinical trials
Also written MSTT1041A and RO7187807.
How each study uses astegolimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2013 (1)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 1
Genentech, Inc. (4) · Hoffmann-La Roche (3) · Amgen (2) · University of Leicester (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test astegolimab, phase 3 first.
- Jun 2027A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)Phase 3 · Hoffmann-La Roche
Studies
Open first, then newest update. How each study uses astegolimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)Active, not recruitingPhase 3Hoffmann-La RocheNCT05878769Written as Astegolimab
- A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary DiseaseCompletedPhase 3Hoffmann-La RocheNCT05595642Written as Astegolimab
- A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary DiseaseCompletedPhase 2Genentech, Inc.NCT05037929Written as Astegolimab
- A Study to Evaluate the Effect of Injection Site on PK of Astegolimab in Healthy SubjectsCompletedPhase 1Genentech, Inc.NCT06462118Written as Astegolimab
- A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic DermatitisCompletedPhase 2Genentech, Inc.NCT03747575Written as MSTT1041A
- A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe AsthmaCompletedPhase 2Hoffmann-La RocheNCT02918019Written as MSTT1041A
- Anti-ST2 (MSTT1041A) in COPD (COPD-ST2OP)CompletedPhase 2University of LeicesterNCT03615040Written as MSTT1041A
- A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 PneumoniaCompletedPhase 2Genentech, Inc.NCT04386616Written as MSTT1041A
- A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.CompletedPhase 1AmgenNCT01928368Written as AMG 282
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal PolypsCompletedPhase 1AmgenNCT02170337Written as AMG 282
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Results posted1
- A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary DiseaseOct 28, 2026NCT05595642
Codes
What other systems call astegolimab · ClinicalTrials.gg INT001457
- MeSH (NLM) C000711667astegolimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 27TW751DTHASTEGOLIMABConfirmed FDA, NLM
- NCI Thesaurus C171824AstegolimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000711667 | astegolimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 27TW751DTH | ASTEGOLIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C171824 | Astegolimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.